Liquid Biopsy in Glioblastoma

Lorian Ronvaux, Matteo RIVA, An Coosemans, Marielle Herzog , Guillaume ROMMELAERE, Nathalie Donis, Lionel D'HONDT, Jonathan Douxfils

Research output: Contribution to journalReview articlepeer-review

Abstract

Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Despite recent advances in therapy modalities, the overall survival of GBM patients remains poor. GBM diagnosis relies on neuroimaging techniques. However, confirmation via histopathological and molecular analysis is necessary. Given the intrinsic limitations of such techniques, liquid biopsy (mainly via blood samples) emerged as a non-invasive and easy-to-implement alternative that could aid in both the diagnosis and the follow-up of GBM patients. Cancer cells release tumoral content into the bloodstream, such as circulating tumor DNA, circulating microRNAs, circulating tumor cells, extracellular vesicles, or circulating nucleosomes: all these could serve as a marker of GBM. In this narrative review, we discuss the current knowledge, the advantages, and the disadvantages of each circulating biomarker so far proposed.

Original languageEnglish
Article number3394
JournalCancers (Basel)
Volume14
Issue number14
DOIs
Publication statusPublished - 13 Jul 2022

Keywords

  • biomarkers
  • circulating microRNAs
  • circulating nucleosomes
  • circulating tumor cells
  • circulating tumor DNA
  • diagnosis
  • extracellular vesicles
  • follow-up
  • glioblastoma

Fingerprint

Dive into the research topics of 'Liquid Biopsy in Glioblastoma'. Together they form a unique fingerprint.

Cite this